Table 1
Open in new tab

Demographic data

REHealthy controlsP
Subjects, n1420n/a
Sex female, n (%)11 (79)13 (65)0.64
Age at MRI, years; median (range)17.5 (7–49)23.5 (9–49)0.74
Age at onset, years; median (range)6 (4–22)n/an/a
Disease duration at MRI, years; median (range)8.5 (0–42)n/an/a
Number of ASM; median (range)6 (0–10)n/an/a
Left hemisphere affected, n (%)8 (57)n/an/a
REHealthy controlsP
Subjects, n1420n/a
Sex female, n (%)11 (79)13 (65)0.64
Age at MRI, years; median (range)17.5 (7–49)23.5 (9–49)0.74
Age at onset, years; median (range)6 (4–22)n/an/a
Disease duration at MRI, years; median (range)8.5 (0–42)n/an/a
Number of ASM; median (range)6 (0–10)n/an/a
Left hemisphere affected, n (%)8 (57)n/an/a

P-values refer to unpaired, two-tailed t-test or chi-squared-test as appropriate. ASM, anti-seizure medication.

Table 1
Open in new tab

Demographic data

REHealthy controlsP
Subjects, n1420n/a
Sex female, n (%)11 (79)13 (65)0.64
Age at MRI, years; median (range)17.5 (7–49)23.5 (9–49)0.74
Age at onset, years; median (range)6 (4–22)n/an/a
Disease duration at MRI, years; median (range)8.5 (0–42)n/an/a
Number of ASM; median (range)6 (0–10)n/an/a
Left hemisphere affected, n (%)8 (57)n/an/a
REHealthy controlsP
Subjects, n1420n/a
Sex female, n (%)11 (79)13 (65)0.64
Age at MRI, years; median (range)17.5 (7–49)23.5 (9–49)0.74
Age at onset, years; median (range)6 (4–22)n/an/a
Disease duration at MRI, years; median (range)8.5 (0–42)n/an/a
Number of ASM; median (range)6 (0–10)n/an/a
Left hemisphere affected, n (%)8 (57)n/an/a

P-values refer to unpaired, two-tailed t-test or chi-squared-test as appropriate. ASM, anti-seizure medication.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close